| Literature DB >> 18445527 |
Jeffrey A Pfefferkorn1, Chulho Choi, Thomas Winters, Robert Kennedy, Liguo Chi, Lisa A Perrin, Gina Lu, Yun-Wen Ping, Tom McClanahan, Richard Schroeder, Michael T Leininger, Andrew Geyer, Sabine Schefzick, James Atherton.
Abstract
The P2Y(1) and P2Y(12) purinergic receptors are responsible for mediating adenosine diphosphate (ADP) dependent platelet aggregation. Evidence from P2Y(1) knockout studies as well as from nucleotide-based small molecule P2Y(1) antagonists has suggested that the antagonism of this receptor may offer a novel and effective method for the treatment of thrombotic disorders. Herein, we report the identification and optimization of a series of non-nucleotide P2Y(1) antagonists that are potent and orally bioavailable.Entities:
Mesh:
Substances:
Year: 2008 PMID: 18445527 DOI: 10.1016/j.bmcl.2008.04.028
Source DB: PubMed Journal: Bioorg Med Chem Lett ISSN: 0960-894X Impact factor: 2.823